News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Promedior Appoints Elizabeth Trehu, M.D., as Chief Medical Officer


10/15/2012 9:50:26 AM

MALVERN, Pa.--(BUSINESS WIRE)--Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, today announced the appointment of Elizabeth G. Trehu, M.D., as Chief Medical Officer (CMO). As CMO, Dr. Trehu will oversee all clinical development and regulatory activities for the company, as Promedior rapidly advances its product candidates in human clinical trials for diseases involving fibrosis, including idiopathic pulmonary fibrosis (IPF), myelofibrosis and retinal diseases. Dr. Trehu is a seasoned biopharmaceutical executive with experience moving early stage R&D programs successfully through clinical development and product commercialization. She will report directly to Promedior’s CEO Suzanne Bruhn, Ph.D., and will serve as a member of the company’s executive management team.

Read at BioSpace.com

comments powered by Disqus
Promedior
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES